{"disease":{"id":"advanced-renal-cell-carcinoma-rcc","name":"advanced renal cell carcinoma rcc"},"drugs":{"marketed":[{"drug_id":"belzutifan","indication_name":"Advanced Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welireg","generic_name":"BELZUTIFAN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"HIF-2α","drug_class":"Hypoxia-inducible Factor Inhibitor [EPC]","quality_score":75,"revenue":"509","mechanism":"Belzutifan inhibits HIF-2α, blocking its interaction with HIF-1β to reduce expression of genes linked to tumor growth."},{"drug_id":"sunitinib","indication_name":"Advanced Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"axitinib-ag-013736","indication_name":"Advanced renal cell carcinoma (RCC) after failure of prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axitinib (AG-013736)","generic_name":"axitinib-ag-013736","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"vascular endothelial growth factor receptors (VEGFRs)","drug_class":"tyrosine kinase inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"axitinib-ag-013736","indication_name":"Advanced renal cell carcinoma (RCC) as a first-line treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axitinib (AG-013736)","generic_name":"axitinib-ag-013736","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"vascular endothelial growth factor receptors (VEGFRs)","drug_class":"tyrosine kinase inhibitor","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT06345183","title":"Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":327,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04957160","title":"Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination","phase":"","overall_status":"COMPLETED","enrollment_count":281,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT07293351","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":234,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07227415","title":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05665361","title":"Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07159191","title":"Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}